NIZO and Enzymit Joined Forces to Successfully Scale Enzyme Production

Ede, the Netherlands & Ness Ziona, Israel – June 24, 2025 – NIZO and Enzymit have successfully partnered to achieve the large-scale production of novel enzymes that is fundamental to Enzymit’s proprietary cell-free manufacturing platform. This ambitious and innovative technology enables the creation of high-value biomolecules—such as Hyaluronic Acid—without the use of living cells. This unique technology and manufacturing process brings to the industry a high quality product and a sustainable alternative to traditional biomanufacturing methods.

Enabling Scalable, Cell-Free Bioproduction

This achievement not only advances the field of bioproduction but also sets a framework for future collaborations aimed at developing sustainable and scalable solutions. By integrating cutting-edge technologies and expertise, Enzymit and NIZO have paved the way for innovations that could redefine industrial enzyme use globally.    

Enzymit’s cell-free platform offers a new approach to bioproduction. Instead of relying on whole cells, it takes a stripped-down, first-principles view of manufacturing. By removing the redundancies and complexities inherent to fermentation, bioproduction becomes not only faster and simpler—but also dramatically more cost-effective.    

Strategic Impact on the Future of Biomanufacturing

This collaboration marks a significant step forward in the industrialization of cell-free manufacturing, a disruptive approach that challenges the limits of traditional microbial or mammalian production systems. The successful scale-up of Enzymit’s enzyme production proves that novel biocatalysts can be reliably produced at scale, paving the way for broader adoption of cell-free platforms in the production of pharmaceuticals, cosmetics, and other high-value biomolecules.

“This project is a great example of how NIZO supports innovative biotech companies in scaling breakthrough technologies,” said Nikolaas Vles, CEO NIZO. “We’re proud to help bring Enzymit’s cell-free manufacturing platform closer to industrial application.”

The collaboration builds on the strengths of both organizations—NIZO’s decades of experience in protein expression and fermentation technologies, and Enzymit’s cutting-edge enzyme design capabilities and cell-free biomanufacturing platform. This partnership highlights the combination of scientific innovation and practical application addressing complex challenges and the growing demand for sustainable manufacturing processes. By reducing reliance on cellular production systems, this cell-free approach also opens new horizons for industries ranging from pharmaceuticals to food technology, advancing efficiency and environmental responsibility.

“Partnering with NIZO allowed us to move quickly from lab-scale to industrially relevant enzyme production,” according to Dr. Gideon Lapidoth, CEO & Co-founder Enzymit. “This collaboration demonstrates the viability of cell-free bioproduction at scale and is a key enabler of our mission to reshape how biomolecules are made.”

Together, NIZO and Enzymit are showcasing a new way forward in biomanufacturing—one that is faster, more flexible, and more sustainable.